Introduction An outbreak of severe acute respiratory syndrome
coronavirus-2 (SARS-CoV-2) was reported in Wuhan, China in mid-December
2019, and declared a pandemic by the World Health Organization (WHO) on
March 11, 2020. Due to the unknown nature of the disease and the lack of
specific drugs, several potential treatments were used for patients.
This systematic review and meta-analysis will evaluate studies of the
effects of Favipiravir in COVID-19 pneumonia. Methods and analysis We
will search electronic databases including LitCovid hub, PubMed, Scopus,
ISI web of Sciences, Cochrane, and Embase using keywords related to
COVID-19 and Favipiravir. To get more news about
Favipiravir, wisepowder official website is the best place for you.
We will search the reference lists of all included studies and reviews.
We will also search for clinical trial registries, such as
clinicaltrial.gov for the ongoing clinical trials. Two investigators
(MAZ and SH) will independently screen titles, abstracts, and full-text
of included studies based on eligibility criteria. These investigators
will also independently extract data and appraise the quality of
studies. All potential discrepancies will be resolved through
consultation with the third reviewer. Data synthesis will be conducted
using the Review Manager software (version 5.3) or CMA (version 2).
Statistical heterogeneity will be assessed using a standard I2 test. A
funnel plot, Egger test, and Begg test will be used for asymmetry to
explore possible publication bias. Ethics and dissemination The findings
of this systematic review with proportional meta-analysis will help to
identify the safety and efficacy of Favipiravir for COVID-19 patients.
Knowledge gained from this research will also assist physicians in
selecting better treatment options and developing a guideline in this
field.
All relevant ethical guidelines have been followed; any necessary IRB
and/or ethics committee approvals have been obtained and details of the
IRB/oversight body are included in the manuscript.
I understand that all clinical trials and any other prospective
interventional studies must be registered with an ICMJE-approved
registry, such as ClinicalTrials.gov. I confirm that any such study
reported in the manuscript has been registered and the trial
registration ID is provided (note: if posting a prospective study
registered retrospectively, please provide a statement in the trial ID
field explaining why the study was not registered in advance).
I have followed all appropriate research reporting guidelines and
uploaded the relevant EQUATOR Network research reporting checklist(s)
and other pertinent material as supplementary files, if applicable.
The Wall